Cargando…
Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401220/ https://www.ncbi.nlm.nih.gov/pubmed/37536935 http://dx.doi.org/10.1136/jitc-2023-007023 |
_version_ | 1785084609982103552 |
---|---|
author | Marcos Rubio, Alvaro Everaert, Celine Van Damme, Eufra De Preter, Katleen Vermaelen, Karim |
author_facet | Marcos Rubio, Alvaro Everaert, Celine Van Damme, Eufra De Preter, Katleen Vermaelen, Karim |
author_sort | Marcos Rubio, Alvaro |
collection | PubMed |
description | The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive biomarkers that can inform clinicians on therapeutic efficacy. All current biomarkers for outcome prediction, including PD-L1, tumor mutational burden or complex immune gene expression signatures, require access to tumor tissue. Besides the invasive nature of the sampling procedure, other disadvantages of tumor tissue biopsies are the inability to capture the complete spatial heterogeneity of the tumor and the difficulty to perform longitudinal follow-up on treatment. A concept emerges in which systemic immune events developing at a distance from the tumor reflect local response or resistance to immunotherapy. The importance of this cancer ‘macroenvironment’, which can be deciphered by comprehensive analysis of peripheral blood immune cell subsets, has been demonstrated in several cutting-edge preclinical reports, and is corroborated by intriguing data emerging from ICI-treated patients. In this review, we will provide the biological rationale underlying the potential of blood immune cell-based biomarkers in guiding treatment decision in immunotherapy-eligible NSCLC patients. Finally, we will describe new techniques that will facilitate the discovery of more immune cell subpopulations with potential to become predictive biomarkers, and reflect on ways and the remaining challenges to bring this type of analysis to the routine clinical care in the near future. |
format | Online Article Text |
id | pubmed-10401220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-104012202023-08-05 Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer Marcos Rubio, Alvaro Everaert, Celine Van Damme, Eufra De Preter, Katleen Vermaelen, Karim J Immunother Cancer Review The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive biomarkers that can inform clinicians on therapeutic efficacy. All current biomarkers for outcome prediction, including PD-L1, tumor mutational burden or complex immune gene expression signatures, require access to tumor tissue. Besides the invasive nature of the sampling procedure, other disadvantages of tumor tissue biopsies are the inability to capture the complete spatial heterogeneity of the tumor and the difficulty to perform longitudinal follow-up on treatment. A concept emerges in which systemic immune events developing at a distance from the tumor reflect local response or resistance to immunotherapy. The importance of this cancer ‘macroenvironment’, which can be deciphered by comprehensive analysis of peripheral blood immune cell subsets, has been demonstrated in several cutting-edge preclinical reports, and is corroborated by intriguing data emerging from ICI-treated patients. In this review, we will provide the biological rationale underlying the potential of blood immune cell-based biomarkers in guiding treatment decision in immunotherapy-eligible NSCLC patients. Finally, we will describe new techniques that will facilitate the discovery of more immune cell subpopulations with potential to become predictive biomarkers, and reflect on ways and the remaining challenges to bring this type of analysis to the routine clinical care in the near future. BMJ Publishing Group 2023-08-03 /pmc/articles/PMC10401220/ /pubmed/37536935 http://dx.doi.org/10.1136/jitc-2023-007023 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Marcos Rubio, Alvaro Everaert, Celine Van Damme, Eufra De Preter, Katleen Vermaelen, Karim Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title | Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title_full | Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title_fullStr | Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title_full_unstemmed | Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title_short | Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
title_sort | circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401220/ https://www.ncbi.nlm.nih.gov/pubmed/37536935 http://dx.doi.org/10.1136/jitc-2023-007023 |
work_keys_str_mv | AT marcosrubioalvaro circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer AT everaertceline circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer AT vandammeeufra circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer AT depreterkatleen circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer AT vermaelenkarim circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer |